CAR-T Cell Therapies Market (2nd Edition) - Trends and Forecast Till 2035

List of Tables

CAR-T CELL THERAPIES MARKET: OVERVIEW

The global CAR-T Cell Therapies market is estimated to grow from USD 7.7 billion in the current year to USD 15.6 billion by 2035, registering a CAGR of 8.1% during the forecast period.

CAR-T Cell Therapies Market: Growth and Trends

Cancer drug development remains a major focus of pharmaceutical investment, with continued regulatory approvals and advances in immuno-oncology expanding the addressable treatment landscape. Within this market, CAR-T therapy has emerged as a leading cell therapy modality, leveraging genetically engineered immune cells to selectively recognize and eliminate cancer cells. Approved therapies have demonstrated the potential to deliver deep and durable responses, including complete remission, particularly in heavily pretreated patients.

The CAR-T development pipeline continues to expand, with nearly 1,000 clinical trials registered over the past eight years and more than 230 companies developing CAR-T candidates across oncology and other therapeutic areas. Six autologous CAR-T Cell Therapies have received FDA approval, covering indications including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. Ongoing label expansions are further widening patient eligibility and commercial opportunities. For instance, the FDA expanded the indication for axicabtagene ciloleucel (Yescarta) to include a rare, aggressive form of non-Hodgkin lymphoma that has progressed following standard treatment.

Regulatory changes are also supporting broader adoption and market access. The FDA removed Risk Evaluation and Mitigation Strategy (REMS) requirements for approved CD19 and BCMA-directed CAR-T Cell Therapies, reducing treatment-site certification requirements, eliminating mandatory tocilizumab stocking, and shortening certain post-infusion monitoring requirements. This regulatory shift is expected to facilitate adoption beyond major academic centers and support the expansion of CAR-T administration into community and regional treatment settings.

Overall, the combination of pipeline expansion, regulatory simplification, label extensions, and broader treatment access is strengthening the commercial outlook for CAR-T Cell Therapies and creating opportunities across cell manufacturing, clinical development, treatment delivery, and supporting infrastructure.

Growth Drivers: Strategic Enablers of Market Expansion

Technological advancement in molecular research. Improvements in CAR construct design, gene transfer methods, and co-stimulatory domains are improving efficacy and expanding the addressable patient population.
Rising demand for personalized cancer treatment. CAR-T's patient-specific, one-time treatment paradigm continues to attract strong physician and patient interest, particularly in relapsed/refractory hematologic malignancies.
Expanding clinical trial activity and approvals. A steady cadence of new approvals and label expansions including into earlier lines of therapy is broadening the eligible patient base.
Sustained investor funding. Continued venture and strategic capital inflow is supporting both autologous pipeline expansion and next-generation allogeneic ("off-the-shelf") platforms.
Regulatory streamlining. Reduced REMS burden and evolving reimbursement frameworks are lowering the operational barrier to broader treatment-center adoption.
Emerging indications beyond oncology. Early clinical and regulatory momentum in autoimmune and dermatologic disease with a first non-oncology CAR-T approval anticipated in the near term points to a meaningfully larger long-term addressable market.

Market Challenges: Barriers to Sustained Growth

Manufacturing complexity and turnaround time. Autologous CAR-T products require patient-specific manufacturing, creating capacity constraints and multi-week vein-to-vein timelines that can be clinically limiting for rapidly progressing disease.
Cold-chain and logistics sensitivity. Cryopreserved apheresis material and finished product must be transported under strict, validated temperature control between treatment centers and manufacturing sites - a significant point of operational risk.
High treatment cost. Approved CAR-T Cell Therapies are priced between roughly USD 373,000 and USD 475,000 per patient, creating access and reimbursement challenges, particularly outside the US and Europe.
Solid tumor limitations. Despite representing the large majority of cancer diagnoses, solid tumors remain largely unaddressed by approved CAR-T therapy due to the immunosuppressive tumor microenvironment, limited T-cell trafficking, antigen heterogeneity, and off-tumor toxicity risk.
Site-of-care constraints. Even with reduced REMS requirements, CAR-T administration still requires specialized infrastructure for cytokine release syndrome and neurotoxicity management, limiting the number of qualified treatment centers.
Competitive and regulatory risk. A crowded pipeline across CD19 and BCMA targets, combined with evolving regional regulatory pathways (US, EU, China), adds commercial and approval-timeline uncertainty for developers.

CAR-T Cell Therapies Market: Key Insights

CAR-T Cell Therapies, with over 1,240 preclinical and clinical product candidates, represent one of the most active segments in the pharmaceutical domain.
Close to 75% of therapy candidates in development are autologous in nature; CD19 and BCMA have emerged as the most popular target antigens.
Extensive efforts are underway to improve CAR constructs across successive generations, including changes to the scFv binding domain and the gene delivery vectors used.
Close to 200 companies claim the capabilities required to manufacture different types of cell therapies, offering services across multiple stages of product development.
More than 970 clinical trials have been registered across geographies for CAR-T Cell Therapies over the past eight years.
Over 375 scientists from leading universities are currently involved in CAR-T clinical development, with key opinion leaders concentrated primarily in the US and China.
Investors have committed more than USD 32 billion across 370+ funding instances, reflecting sustained confidence in the segment.
More than 11,900 patents related to CAR-T Cell Therapies have been filed or granted, underscoring the intensity of intellectual property activity in this field.

Recent Developments Signaling Market Momentum

The FDA removed REMS requirements for all approved CD19- and BCMA-directed CAR-T Cell Therapies, easing site-certification and monitoring burdens and supporting wider treatment-center adoption.
The FDA expanded the label for Yescarta (axicabtagene ciloleucel) to include patients with relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma.
The FDA granted IND clearance to KLN-1010, an in vivo gene therapy approach for relapsed/refractory multiple myeloma, following encouraging early clinical data part of a broader wave of next-generation, off-the-shelf CAR-T platform development.
The first international patient was treated with a newly approved solid-tumor CAR-T therapy at a cancer center in China, an early but notable step toward addressing the solid tumor opportunity that has so far eluded approved CAR-T products.
Clinical and regulatory momentum continued to build toward the field's first CAR-T approval outside oncology, with an autoimmune/dermatologic indication anticipated as a near-term milestone.
Allogeneic ("off-the-shelf") CAR-T developers, including programs from multiple biotech innovators, continued reporting clinical readouts across oncology and autoimmune disease, aiming to eliminate the patient-specific manufacturing window that currently constrains capacity and access.

CAR-T Cell Therapies Market Segmentation

The market sizing and opportunity analysis is segmented across the following parameters:

By Target Indication

Acute Lymphoblastic Leukemia
Diffuse Large B-cell Lymphoma
Follicular Lymphoma
Large B-cell Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Others

By Target Antigen

CD19
BCMA
CD20
CD19 / CD22
Others

By Key Geographical Region

North America (US, Canada)
Europe (Germany, France, Italy, Spain, UK, Rest of Europe)
Asia-Pacific (Japan, India, China, Australia, South Korea, Rest of Asia-Pacific)
Latin America
Middle East and North Africa
Rest of the World

By Key Drugs

Yescarta
Kymriah
Abecma
Breyanzi
Carvykti
Tecartus
Others (including pipeline candidates)

CAR-T Cell Therapies Market: Key Segment Insights

Multiple Myeloma Holds Highest Share

Multiple myeloma currently holds the largest share of CAR-T cell therapy market. This highest share is supported by the high unmet need in relapsed or refractory disease, frequent disease recurrence, and limited treatment options after standard therapies. Further, the FDA has approved two BCMA-targeted CAR-T Cell Therapies for patients who have received first-lines of treatment, expanding the addressable patient population and strengthening the segment's commercial potential.

Large B-cell lymphoma is projected to register the highest growth during the forecast period, driven by its sizeable patient population, high relapse rates, and increasing adoption of CAR-T Cell Therapies in relapsed or refractory disease. Ongoing evaluation of CAR-T Cell Therapies in earlier treatment lines is expected to further expand patient eligibility and accelerate market adoption.

Across adjacent targeted therapy markets, HER2-targeting therapies address HER2-driven cancers through a range of modalities, including antibodies, antibody-drug conjugates, bispecific antibodies, and cellular therapies.

CD19-Targeted Therapies Maintain Market Leadership

CD19 accounted for the highest CAR-T cell therapy market share. This dominance is driven by extensive clinical validation across B-cell malignancies, including acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. The commercial availability of multiple CD19-directed CAR-T Cell Therapies, including Kymriah, Yescarta, Breyanzi, and Aucatzyl, has further strengthened the segment's market position.

BCMA is projected to register the highest CAGR through 2035. This lucrative growth is due to the increasing adoption of BCMA-directed CAR-T Cell Therapies for multiple myeloma. Strong clinical outcomes, expansion into earlier treatment lines, and growing physician familiarity are supporting broader use of this target. Commercial momentum from Carvykti and Abecma is expected to further reinforce BCMA as a key growth opportunity within the CAR-T market.

North America Leads While Asia-Pacific Offers High-Growth Potential

North America currently represents the largest regional market, supported by its concentration of approved CAR-T Cell Therapies, specialized treatment centers, manufacturing capabilities, and established reimbursement infrastructure. Asia-Pacific is projected to register the fastest growth through 2035. Expanding domestic development pipelines, increasing treatment capacity, and evolving regulatory frameworks are expected to support broader regional adoption and create new opportunities for CAR-T developers and service providers.

Example Players in the CAR-T Cell Therapies Market

Autolus
bluebird bio
Bristol Myers Squibb
CARsgen Therapeutics
Cellectis
Gilead Sciences (Kite Pharma)
Innovative Cellular Therapeutics
Noile-Immune Biotech
Novartis
Shanghai GeneChem
Sinobioway Cell Therapy
Takara Bio
Wellington Zhaotai Therapies

CAR-T CELL THERAPIES MARKET: RESEARCH COVERAGE

This CAR-T Cell Therapies market report provides:

Market Forecast and Opportunity Analysis across target antigen, target indication, key geographical regions, sales forecast of drugs, and leading players
Market Impact Analysis covering drivers, restraints, opportunities, and challenges
Market Landscape assessment by developer type, phase of development, therapeutic area, target antigen, source of T-cells, route of administration, and company profile parameters
Clinical Trial Analysis by registration year, enrollment, trial phase, sponsor type, and regional distribution
CAR Construct Analysis by CAR generation, binding domain, viral vector, gene transfer method, and co-stimulatory domain
Key Opinion Leader (KOL) Analysis of principal investigators active in CAR-T clinical research
Company Profiles of leading and emerging CAR-T developers, including manufacturing capabilities and strategic investment activity
Partnerships, Funding, and Patent Analysis covering deal activity, investment trends, and IP landscape
Case Study: Cell Therapy Manufacturing comparing centralized and decentralized manufacturing models and contract manufacturing versus in-house capabilities
Cost and Pricing Analysis of factors driving CAR-T therapy pricing and reimbursement considerations

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in the CAR-T Cell Therapies market?
Which companies lead the CAR-T Cell Therapies market?
What is the current and projected market size?
Which region dominates, and which is growing fastest?
What is driving growth in the CAR-T Cell Therapies market?
What are the main challenges facing the market?
What opportunities exist for distributors and logistics partners?

REASONS TO BUY THIS REPORT

Comprehensive revenue projections for the overall CAR-T Cell Therapies market and its individual sub-segments, valuable to both established market leaders and emerging entrants.
Competitive dynamics analysis enabling businesses to optimize market positioning and develop effective go-to-market strategies.
A full view of drivers, barriers, opportunities, and challenges, empowering stakeholders to make data-driven decisions and capitalize on growth prospects.
Detailed clinical trial, patent, and funding analysis providing an evidence-based view of where R&D and investor attention are concentrated.
Company-level manufacturing and capability data, useful for distributors and logistics partners assessing where to focus cold-chain and access-support investment.

ADDITIONAL BENEFITS

Complimentary PPT insights pack
Complimentary Excel data packs for all analytical modules in the report
15% free content customization
Detailed report walkthrough session with the research team
Free updated report if the edition is 6-12 months old or older

Product Code: RA100389

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product (GDP)
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of T-cell Immunotherapies
- 6.2.1. Historical Evolution
- 6.2.2. Key Considerations for Developing T-cell Immunotherapies
- 6.2.3. Strategies Employed for the Redirection of T-cells
- 6.2.4. Manufacturing of Engineered T-cells
6.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
- 6.3.1. Development History
- 6.3.2. Structure of CAR
  - 6.3.2.1. Ectodomain
  - 6.3.2.2. Transmembrane (TM) Domain
  - 6.3.2.3. Endodomain
- 6.3.3. Development of CAR-T Cells
- 6.3.4. Universal CAR-T Cells
- 6.3.5. Route of Administration
- 6.3.6. Challenges Associated with CAR-T Cell Therapies
  - 6.3.6.1. Competitive Risks
  - 6.3.6.2. Clinical Risks
  - 6.3.6.3. Regulatory Risks
  - 6.3.6.4. Commercial Risks
6.4. Concluding Remarks

7. CAR-T CELL THERAPIES: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Market Landscape
- 7.2.1. Analysis by Stage of Development
- 7.2.2. Analysis by Type of Therapy
- 7.2.3. Analysis by Target Antigen
- 7.2.4. Analysis by Target Indication
- 7.2.5. Analysis by Therapeutic Area
- 7.2.6. Analysis by Stage of Development and Therapeutic Area
- 7.2.7. Analysis by Source of T-cells
- 7.2.8. Analysis by Stage of Development and Source of T-cells
- 7.2.9. Analysis by Route of Administration
- 7.2.10. Analysis by Dosage Regimen
- 7.2.11. Analysis by Target Patient Population
- 7.2.12. Most Active Industry Players: Analysis by Number of Therapies
- 7.2.13. Most Active Non-Industry Players: Analysis by Number of Therapies
7.3. CAR-T Cell Therapies: Overall Developer Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters

8. KEY INSIGHTS

8.1. Chapter Overview
8.2. CAR-T Cell Therapies: Popular Target Antigens
- 8.2.1. Popular Targets for Hematological Malignancies
- 8.2.2. Popular Targets for Solid Tumors
8.3. CAR-T Therapies: CAR Construct Analysis
- 8.3.1. Analysis by Generation of CAR
- 8.3.2. Analysis by Type of scFv Antibody Used
- 8.3.3. Analysis by Type of Virus Used
- 8.3.4. Analysis by Type of Gene Transfer Method Used
- 8.3.5. Analysis by Type of Co-Stimulatory Domain

9. CLINICAL TRIAL ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. CAR-T Cell Therapies: Clinical Trial Analysis
- 9.3.1. Analysis by Trial Registration Year
- 9.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
- 9.3.3. Analysis by Trial Phase
- 9.3.4. Analysis of Enrolled Patient Population by Trial Phase
- 9.3.5. Analysis by Trial Registration Year and Trial Phase
- 9.3.6. Analysis by Trial Status
- 9.3.7. Analysis by Patient Gender
- 9.3.8. Analysis by Therapeutic Area
- 9.3.9. Analysis by Study Design
- 9.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
- 9.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
- 9.3.12. Analysis by Geography

10. KEY OPINION LEADERS

10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. CAR-T Cell Therapies: Key Opinion Leaders
- 10.4.1. Analysis by Type of Organization
- 10.4.2. Analysis by Affiliated Organization
- 10.4.3. Analysis by Geographical Location of KOLs
- 10.4.4. KOL Activeness versus KOL Strength
- 10.4.5. Most Prominent KOLs: Analysis by RA score
- 10.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

11. COMPANY PROFILES

11.1. Chapter Overview
11.2. Autolus
11.3. Bluebird Bio
11.4. Bristol Myers Squibb
11.5. CARsgen Therapeutics
11.6. Cellectis
11.7. Gilead Sciences
11.8. Innovative Cellular Therapeutics
11.9. Noile-Immune Biotech
11.10. Novartis
11.11. Sinobioway Cell Therapy
11.12. Takara Bio
11.13. Wellington Zhaotai Therapies

12. PARTNERSHIPS AND COLLABORATIONS

12.1. Chapter Overview
12.2. Partnership Models
12.3. CAR-T Cell Therapies: Partnerships and Collaborations
- 12.3.1. Analysis by Year of Partnership
- 12.3.2. Analysis by Type of Partnership
- 12.3.3. Analysis by Year and Type of Partnership
- 12.3.4. Analysis by Type of Partner
- 12.3.5. Most Popular Therapies: Analysis by Number of Partnerships
- 12.3.6. Most Active Industry Players: Analysis by Number of Partnerships
- 12.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
- 12.3.8. Analysis by Geography
  - 12.3.8.1. Intercontinental and Intracontinental Agreements
  - 12.3.8.2. International and Local Agreements

13. FUNDING AND INVESTMENTS ANALYSIS

13.1. Chapter Overview
13.2. Types of Funding
13.3. CAR-T Cell Therapies: Funding and Investment Analysis
- 13.3.1. Analysis by Year of Funding
- 13.3.2. Analysis of Amount Invested
- 13.3.3. Analysis by Type of Funding
- 13.3.4. Analysis by Amount Invested and Type of Funding
- 13.3.5. Analysis of Amount Invested by Year and Type of Funding
- 13.3.6. Analysis by Type of Investor
- 13.3.7. Analysis by Geography
- 13.3.8. Most Active Players
- 13.3.9. Leading Investors: Analysis by Number of Funding Instances

14. PATENT ANALYSIS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. CAR-T Cell Therapies: Patent Analysis
- 14.3.1. Analysis by Patent Publication Year
- 14.3.2. Analysis by Patent Application Year
- 14.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
- 14.3.4. Analysis by Patent Jurisdiction
- 14.3.5. Analysis by CPC Symbols
- 14.3.6. Analysis by Type of Applicant
- 14.3.7. Leading Industry Players: Analysis by Number of Patents
- 14.3.8. Leading Non-Industry Players: Analysis by Number of Patents
- 14.3.9. Leading Patent Assignees: Analysis by Number of Patents
14.4. Patent Benchmarking Analysis
- 14.4.1. Analysis by Patent Characteristics
14.5. Patent Valuation
14.6. Leading Patents by Number of Citations

15. CASE STUDY: CELL THERAPY MANUFACTURING

15.1. Chapter Overview
15.2. Overview of Cell Therapy Manufacturing
15.3. Cell Therapy Manufacturing Models
- 15.3.1. Centralized Manufacturing Model
- 15.3.2. Decentralized Manufacturing Model
15.4. Scalability of Cell Therapy Manufacturing Processes
- 15.4.1. Scale-Up
- 15.4.2. Scale-Out
15.5. Types of Cell Therapy Manufacturers
15.6. Key Challenges Related to Manufacturing of Cell Therapies
15.7. Key Considerations for Cell Therapy Manufacturing
- 15.7.1. Characterization
- 15.7.2. Cost of Goods
15.8. Automation of Cell Therapy Manufacturing Process
15.9. Cell Therapy Manufacturing Supply Chain
15.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
15.11. Regulatory Landscape
15.12. Future Perspectives

16. COST PRICE ANALYSIS

16.1. Chapter Overview
16.2. Factors Contributing to the High Price of Cell / Gene Therapies
16.3. Pricing Models for T-cell Immunotherapies
- 16.3.1. Based on Associated Costs
- 16.3.2. Based on Availability of Competing Products
- 16.3.3. Based on Patient Population
- 16.3.4. Based on Opinions of Industry Experts
16.4. Reimbursement related Considerations for T-cell Immunotherapies
- 16.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

17. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

17.1. Chapter Overview
17.2. Market Drivers
17.3. Market Restraints
17.4. Market Opportunities
17.5. Market Challenges
17.6. Conclusion

18. GLOBAL CAR-T CELL THERAPY MARKET

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Global CAR-T Cell Therapy Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
18.4. Scenario Analysis
- 18.4.1. Conservative Scenario
- 18.4.2. Optimistic Scenario
18.5. Key Market Segmentations

19. CAR-T CELL THERAPY MARKET, BY PRODUCT

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. CAR-T Cell Therapy Market: Distribution by Product
- 19.3.1. CAR-T Cell Therapy Market for Abecma: Forecasted Estimates (till 2035)
- 19.3.2. CAR-T Cell Therapy Market for Breyanzi: Forecasted Estimates (till 2035)
- 19.3.3. CAR-T Cell Therapy Market for Carvykti: Forecasted Estimates (till 2035)
- 19.3.4. CAR-T Cell Therapy Market for Kymriah: Forecasted Estimates (till 2035)
- 19.3.5. CAR-T Cell Therapy Market for Tecartus: Forecasted Estimates (till 2035)
- 19.3.6. CAR-T Cell Therapy Market for Yescarta: Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation

20. CAR-T CELL THERAPY MARKET, BY TYPE OF THERAPY

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. CAR-T Cell Therapy Market: Distribution by Type of Therapy
- 20.3.1. CAR-T Cell Therapy Market for Autologous CAR-T Cell Therapy: Forecasted Estimates (till 2035)
- 20.3.2. CAR-T Cell Therapy Market for Allogeneic CAR-T Cell Therapy: Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation

21. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. CAR-T Cell Therapy Market: Distribution by Target Antigen
- 21.3.1. CAR-T Cell Therapy Market for CD19: Forecasted Estimates (till 2035)
- 21.3.2. CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (till 2035)
- 21.3.3. CAR-T Cell Therapy Market for CD20: Forecasted Estimates (till 2035)
- 21.3.4. CAR-T Cell Therapy Market for CD19/22: Forecasted Estimates (till 2035)
- 21.3.5. CAR-T Cell Therapy Market for Other Target Antigens: Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation

22. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. CAR-T Cell Therapy Market: Distribution by Target Indication
- 22.3.1. CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (till 2035)
- 22.3.2. CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (till 2035)
- 22.3.3. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (till 2035)
- 22.3.4. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (till 2035)
- 22.3.5. CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (till 2035)
- 22.3.6. CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (till 2035)
- 22.3.7. CAR-T Cell Therapy Market for Others: Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation

23. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY GEOGRAPHICAL REGIONS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions
- 23.3.1. CAR-T Cell Therapy Market in North America: Forecasted Estimates (till 2035)
- 23.3.2. CAR-T Cell Therapy Market in Europe: Forecasted Estimates (till 2035)
- 23.3.3. CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (till 2035)
- 23.3.4. CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (till 2035)
- 23.3.5. CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (till 2035)
- 23.3.6. CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation

24. CAR-T CELL THERAPY MARKET, SALES FORECAST OF DRUGS

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Commercialized CAR-T Cell Therapies: Sales Forecast
24.4. Clinical CAR-T Cell Therapies: Sales Forecast
24.5. Data Triangulation and Validation

25. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. CAR-T Cell Therapies: Leading Players
- 25.3.1. Gilead Sciences Sales Forecast
- 25.3.2. Bristol Myers Squibb Sales Forecast
- 25.3.3. Novartis Sales Forecast
- 25.3.4. Janssen Sales Forecast
- 25.3.5. JW Therapeutics Sales Forecast
25.4. Data Triangulation and Validation

26. PROMOTIONAL ANALYSIS

26.1. Chapter Overview
26.2. Channels Used for Promotional Campaigns
26.3. Summary of Product Website Analysis
26.4. Summary of Patient Support Services and Informative Downloads
26.5. Kymriah: Promotional Analysis
- 26.5.1. Drug Overview
- 26.5.2. Product Website Analysis
  - 26.5.2.1. Message for Healthcare Professionals
  - 26.5.2.2. Message for Patients
  - 26.5.2.3. Informative Downloads
- 26.5.3. Patient Support Services
26.6. Yescarta: Promotional Analysis
- 26.6.1. Drug Overview
- 26.6.2. Product Website Analysis
  - 26.6.2.1. Message for Healthcare Professionals
  - 26.6.2.2. Message for Patients
  - 26.6.2.3. Informative Downloads
- 26.6.3. Patient Support Services
26.7. Tecartus: Promotional Analysis
- 26.7.1. Drug Overview
- 26.7.2. Product Website Analysis
  - 26.7.2.1. Message for Healthcare Professionals
  - 26.7.2.2. Message for Patients
  - 26.7.2.3. Informative Downloads
- 26.7.3. Patient Support Services
26.8. Breyanzi: Promotional Analysis
- 26.8.1. Drug Overview
- 26.8.2. Product Website Analysis
  - 26.8.2.1. Message for Healthcare Professionals
  - 26.8.2.2. Message for Patients
  - 26.8.2.3. Informative Downloads
- 26.8.3. Patient Support Services
26.9. Abecma: Promotional Analysis
- 26.9.1. Drug Overview
- 26.9.2. Product Website Analysis
  - 26.9.2.1. Message for Healthcare Professionals
  - 26.9.2.2. Message for Patients
  - 26.9.2.3. Informative Downloads
- 26.9.3. Patient Support Services
26.10. Carvykti: Promotional Analysis
- 26.10.1. Drug Overview
- 26.10.2. Product Website Analysis
  - 26.10.2.1. Message for Healthcare Professionals
  - 26.10.2.2. Message for Patients
  - 26.10.2.3. Informative Downloads
- 26.10.3. Patient Support Services

27. EXECUTIVE INSIGHTS

28. CONCLUDING REMARKS

29. APPENDIX I: TABULATED DATA

30. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

31. APPENDIX III: LIST OF FUNDING AND INVESTMENTS